Cardica Appoints Industry Veteran Liam Burns As Vice President, Sales And Marketing
REDWOOD CITY, Calif., Jan. 13, 2014 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced it has appointed Liam Burns to the position of Vice President, Sales and Marketing.
"Liam has been working with Cardica for several years, and has helped us to establish relationships with key U.S. surgeons interested in the MicroCutter XCHANGE™ 30," said Bernard A. Hausen, M.D., Ph.D., president and CEO of Cardica. "As we begin our selective introduction of the MicroCutter XCHANGE 30 to key accounts in the US, and seek to expand our presence in the European Union, Liam's expertise in product introductions and his network of relationships with surgeons will be instrumental in the commercialization of the MicroCutter XCHANGE 30."
Mr. Burns brings more than 20 years of medical device sales and marketing expertise to Cardica. Most recently, he served as president of a strategic marketing and sales practice he founded to help healthcare and life science companies accelerate product sales and market growth through executive leadership development, effective sales and marketing programs and key business processes. Earlier in his career, he served as vice president of marketing at Power Medical Interventions, Inc. leading a global team responsible for all aspects of marketing, sales, clinical affairs and physician education. Previously, he served in escalating roles at Johnson & Johnson – Ethicon, Inc., most recently as group marketing director for biosurgicals. Prior to his experience in the medical device industry, he served as a lieutenant in the United States Navy. He received an MBA from Case Western Reserve University, and a bachelors of arts in economics from the College of the Holy Cross. He is the author of numerous healthcare publications.
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to reduce operating time and facilitate minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its MicroCutter XCHANGE™ 30, a cartridge-based surgical stapling device with a five-millimeter shaft diameter, for use in a variety of gastrointestinal procedures and appendectomies in the United States and a wide range of surgical procedures in Europe. Cardica is developing the Cardica® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device with an eight-millimeter shaft to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 45 product requires 510(k) review and CE Mark and is not yet commercially available in the U.S. or internationally. In addition, Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 47,700 units throughout the world.
The statement in this press release regarding Cardica's intent to implement a selective commercial launch of the XCHANGE 30 in the United States in the months ahead is a "forward-looking statement." There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including: that surgeons may not use the XCHANGE 30 correctly, which could cause unfavorable results that may impair the acceptance of the XCHANGE 30 by other surgeons; and that Cardica may not have sufficient funds to commercialize the XCHANGE 30, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, under the caption "Risk Factors." Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
SOURCE Cardica, Inc.